Xenon Pharmaceuticals Inc. (NASDAQ:XENE) major shareholder Bvf Partners L. P/Il purchased 41,344 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were bought at an average cost of $2.70 per share, for a total transaction of $111,628.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Xenon Pharmaceuticals Inc. (XENE) traded up 8.16% during trading on Wednesday, reaching $2.65. 132,571 shares of the company traded hands. Xenon Pharmaceuticals Inc. has a 12-month low of $2.25 and a 12-month high of $9.95. The firm’s market capitalization is $47.69 million. The company has a 50 day moving average price of $3.13 and a 200 day moving average price of $4.94.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative net margin of 3,489.63% and a negative return on equity of 47.53%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.38 million. On average, equities analysts predict that Xenon Pharmaceuticals Inc. will post ($0.96) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Xenon Pharmaceuticals Inc. (XENE) Major Shareholder Buys $111,628.80 in Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/xenon-pharmaceuticals-inc-xene-major-shareholder-buys-111628-80-in-stock.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XENE. Scotia Capital Inc. increased its position in Xenon Pharmaceuticals by 36.0% in the second quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 9,426 shares during the last quarter. KCG Holdings Inc. bought a new position in Xenon Pharmaceuticals during the first quarter worth about $122,000. K2 Principal Fund L.P. increased its position in Xenon Pharmaceuticals by 104.4% in the first quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 59,747 shares during the last quarter. Renaissance Technologies LLC increased its position in Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after buying an additional 102,890 shares during the last quarter. Finally, Sabby Management LLC bought a new position in Xenon Pharmaceuticals during the first quarter worth about $1,186,000. Institutional investors own 56.01% of the company’s stock.

Several research firms have recently commented on XENE. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Jefferies Group LLC reissued a “buy” rating and set a $8.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, June 12th. Finally, Canaccord Genuity reissued a “buy” rating and set a $5.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 27th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $11.88.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Insider Buying and Selling by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.